The commercialization of genome-editing technologies
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abundant evidence demonstrates that CRISPR-Cas systems could be used to improve nutrient content in foods113–122.”
From CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool (2019) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · cited 1×
“However, these technologies have had limited use due to design complexity, transfection inefficiencies and limitations in multiplexed mutations [3].”
BackgroundGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 1×
“Currently, several genetically engineered therapeutic strategies aside from CRISPR have been utilized in oncology clinical trials and are on the path toward regulatory approval [39].”
BackgroundCRISPR/Cas9-mediated gene editing in human tripronuclear zygotes
Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., Li, Y., et al. (2015) · Protein & Cell · doi:10.1007/s13238-015-0153-5 · Cited by 1,135 · cited 1×
“viable human embryos [5], genetic screening of”
Lawrenson, T., Shorinola, O., Stacey, N., Li, C., Østergaard, L., Patron, N., Uauy, C., & Harwood, W. (2015) · Genome Biology · doi:10.1186/s13059-015-0826-7 · Cited by 551
Research works printed but not linked: 31
- 10.1016/j.coviro.2015.03.011 · DOI
- Precision Biosciences and Cellectis SA Announce Cross-License and Settlement Agreement for Gene Editing Technology, Press Release, Cellectis. [cited 2016 Sep 22]. Available from: http://www.cellectis.com/en/content/precision-biosciences-and-cellectis-sa-announce-cross-license-and-settlement-agreement-gen-0.
- Cellectis and Thermo Fisher Scientific Enter into Agreements on Talen™, a Leading Gene Editing Technology, Press Release, Cellectis. [cited 2016 Sep 22]. Available from: http://www.cellectis.com/en/content/cellectis-and-thermo-fisher-scientific-enter-agreements-talentm-leading-gene-editing-0
- 10.1038/531149a · DOI
- 10.1038/532172a · doi:10.1038/532172a
- The data was compiled from press releases from the company websites, Keywords searched were “company name”, “gene editing technology”, and “license agreements” in Google. [cited 2016 Jan 15]. Available from: https://www.google.com/#q=Gene+Editing+Technology+License+Agreements
- Zhang F., 2014, CRISPR-Cas systems and methods for altering expression of gene products
- May AP, 2014, . WO2014150624 A1
- Le Buhan C., China. [cited 2016 May 25]. Available from:
- 10.1038/nbt.3590 · DOI
- 10.1016/j.irle.2009.06.001 · DOI
- 10.1038/nbt.3086 · DOI
- Sherkow JS., 2016, Biochemist e-volution, 38, 26, 10.1042/BIO03803026 · DOI
- 10.1172/JCI72992 · DOI · Paper page
- 10.1111/pbi.12444 · DOI · Paper page
- Fisher Scientific Completes Acquisition of Dharmacon; Expands Its Portfolio of Proprietary Products, Press Release, Thermofisher Scientific, Hampton, Nh. [cited 2016 May 25]. Available from: http://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2004/Fisher-Scientific-Completes-Acquisition-of-Dharmacon-Expands-Its-Portfolio-of-Proprietary-Products/default.aspx
- Editas Medicine Raises $120 Million to Advance Genome Editing, Editas, Cambridge, MA. [cited 2016 May 25]. Available from: http://ir.editasmedicine.com/phoenix.zhtml?c=254265&p=irol-newsArticle&ID=2125221
- Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology, Business Wire, Cambridge, MA. [cited 2016 May 25]. Available from: http://www.businesswire.com/news/home/20141118005077/en/Intellia-Therapeutics-Announces-15-Million-Funding-Develop
- Bayer and CRISPR Therapeutics AG Join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases, Press Release, Bayer, Leverkusen, Germany and Basel, Switzerland. [cited 2016 May 25]. Available from: http://www.bayer.nl/nl/media/nieuws/bayer-and-crispr-therapeutics-ag-join-forces-to-discover-develop-and-commercialize-potential-cures-for-serious-genetic-diseases.php
- Baxalta and Precision Biosciences Form Global Genome Editing Collaboration in Immuno-Oncology, Press Release, Precision Biosciences, Durham, North Carolina. [cited 2016 May 25]. Available from: http://precisionbiosciences.com/baxalta-and-precision-biosciences-form-global-genome-editing-collaboration-in-immuno-oncology/
- 10.1038/nbt0609-531 · doi:10.1038/nbt0609-531
- 10.1038/nature.2016.19718 · DOI
- 10.1038/nature.2016.19754 · DOI · Paper page
- 10.2174/1566524016666160316150847 · doi:10.2174/1566524016666160316150847
- 10.1101/gr.162339.113 · DOI · Paper page
- 10.1093/nar/gku402 · DOI · Paper page
- 10.1038/nmeth.2857 · DOI · Paper page
- 10.1016/j.crvi.2003.09.017 · doi:10.1016/j.crvi.2003.09.017
- 10.1007/s10815-016-0753-x · doi:10.1007/s10815-016-0753-x
- 10.1038/nature.2015.17378 · DOI
- 10.1038/nature.2016.19270 · DOI
Cited by
CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
Clapp, J., & Ruder, S.-L. (2020) · Global Environmental Politics · doi:10.1162/glep_a_00566 · Cited by 251
Fourth generation biofuel from genetically modified algal biomass: Challenges and future directions.
Shokravi, H., Shokravi, Z., Heidarrezaei, M., Ong, H. C., Rahimian Koloor, S. S., Petrů, M., Lau, W. J., & Ismail, A. F. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.131535 · Cited by 127
Snipping around for food: economic, ethical and policy implications of CRISPR/Cas genome editing
Bartkowski, B., Theesfeld, I., Pirscher, F., & Timaeus, J. (2018) · Geoforum · doi:10.1016/j.geoforum.2018.07.017 · Cited by 81
Metadata
- Authors
- Brinegar, K., K. Yetisen, A., Choi, S., Vallillo, E., Ruiz-Esparza, G. U., Prabhakar, A. M., Khademhosseini, A., & Yun, S.-H.
- Affiliations
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA;
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, USA;
- Department of Radiology, Division of Cardiovascular Imaging, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA;
- Venue
- Critical Reviews in Biotechnology
- Publisher
- Informa UK Limited
- Published
- 2017-01-18
- Volume
- 37
- Issue
- 7
- Pages
- 924-932
- ISSN
- 0738-8551
- 1549-7801
- Cited by
- 77
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The commercialization of genome-editing technologies. https://app.cochat.ai/papers/10.1080/07388551.2016.1271768
- The paper
- Brinegar, K., K. Yetisen, A., Choi, S., Vallillo, E., Ruiz-Esparza, G. U., Prabhakar, A. M., Khademhosseini, A., & Yun, S.-H. (2017). The commercialization of genome-editing technologies. Critical Reviews in Biotechnology. https://doi.org/10.1080/07388551.2016.1271768
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.